TGF-β in blood: A complex problem

Cytokine and Growth Factor Reviews

Volumn 11, Issue 1-2, 2000, Pages 133-145

  Grainger, David J ^a   Mosedale, David E ^a   Metcalfe, James C ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Blood clot; ELISA; Plasma; TGF ; Wound healing

Indexed keywords

TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TRANSFORMING GROWTH FACTOR BETA3;

ADULT; AGE; AGED; ANIMAL; BLOOD; BLOOD ANALYSIS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GEOGRAPHIC DISTRIBUTION; HUMAN; LEUKOCYTE; LIQUID CHROMATOGRAPHY; MALE; METABOLISM; METHODOLOGY; PLASMA; PROTEIN BLOOD LEVEL; PROTEIN LOCALIZATION; REFERENCE VALUE; REVIEW; SEX; THROMBOCYTE; URINE;

ANIMALS; BLOOD PLATELETS; CHROMATOGRAPHY, LIQUID; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; REFERENCE VALUES; TRANSFORMING GROWTH FACTOR BETA;

ANIMALIA;

EID: 0034022167     PISSN: 13596101     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6101(99)00037-4     Document Type: Review

References (81)

1. Clark D.A., Coker R. Transforming growth factor-beta (TGF-beta). Int. J. Biochem. Cell Biol. 30:1998;293-298.
2. Assoian R.K., Komoriya A., Meyers C.A., Miller D.M., Sporn M.B. Transforming growth factor-beta in human platelets. Identification of a major storage site, purification, and characterization. J. Biol. Chem. 258:1983;7155-7160.
3. Gray A.M., Mason A.J. Requirement for activin A and transforming growth factor-beta 1 pro-regions in homodimer assembly. Science. 247:1990;1328-1330.
4. Miyazono K., Olofsson A., Colosetti P., Heldin C.H. A role of the latent TGF-beta-1-binding protein in the assembly and secretion of TGF-beta-1. Embo Journal. 10:1991;1091-1101.
5. Sinha S., Nevett C., Shuttleworth C.A., Kielty C.M. Cellular and extracellular biology of the latent transforming growth factor-beta binding proteins. Matrix Biol. 17:1998;529-545.
6. Dennis P.A., Rifkin D.B. Cellular activation of latent transforming growth-factor-beta requires binding to the cation-independent mannose 6-phosphate insulin-like growth-factor type-ii receptor. Proc. Natl. Acad. Sci., USA. 88:1991;580-584.
7. Munger J.S., Harpel J.G., Gleizes P.E., Mazzieri R., Nunes I., Rifkin D.B. Latent transforming growth factor-beta: structural features and mechanisms of activation. Kidney International. 51:1997;1376-1382.
8. Crawford S.E., Stellmach V., Murphy-Ullrich J.E., Ribeiro S.M., Lawler J., Hynes R.O., Boivin G.P., Bouck N. Thrombospondin-1 is a major activator of TGF-beta1 in vivo. Cell. 93:1998;1159-1170.
9. Schultz-Cherry S., Murphy-Ullrich J.E. Thrombospondin causes activation of latent transforming growth factor-beta secreted by endothelial cells by a novel mechanism. J. Cell Biol. 122:1993;923-932.
10. Munger J.S., Huang X., Kawakatsu H., Griffiths M.J., Dalton S.L., Wu J., Pittet J.F., Kaminski N., Garat C., Matthay M.A., Rifkin D.B., Sheppard D. The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell. 96:1999;319-328.
11. Massagué J. TGF-beta signal transduction. Annu. Rev. Biochem. 67:1998;753-791.
12. Border W.A., Ruoslahti E. Transforming growth factor-beta in disease: the dark side of tissue repair. Journal of Clinical Investigation. 90:1992;1-7.
13. Akhurst R.J., Balmain A. Genetic events and the role of TGF beta in epithelial tumour progression. J. Pathol. 187:1999;82-90.
14. Grainger D.J., Metcalfe J.C. A pivotal role for TGF-beta in atherogenesis? Biological Reviews of the Cambridge Philosophical Society. 70:1995;571-596.
15. Fujita T., Matsui T., Nakao Y., Shiozawa S., Imai Y. Cytokines and osteoporosis. Ann. NY Acad. Sci. 87:1990;371-375.
16. Grainger D.J., Percival J., Chiano M., Spector T.D. The role of serum TGF-beta isoforms as potential markers of osteoporosis. Osteoporos Int. 9:1999;398-404.
17. Pratt B.M., McPherson J.M. TGF-beta in the central nervous system: potential roles in ischemic injury and neurodegenerative diseases. Cytokine Growth Factor Rev. 8:1997;267-292.
18. Shirai Y., Kawata S., Tamura S., Ito N., Tsushima H., Takaishi K., Kiso S., Matsuzawa Y. Plasma transforming growth factor-beta 1 in patients with hepatocellular carcinoma. Comparison with chronic liver diseases. Cancer. 73:1994;2275-2279.
19. Ivanovic V., Melman A., Davis-Joseph B., Valcic M., Geliebter J. Elevated plasma levels of TGF-beta 1 in patients with invasive prostate cancer. Nat. Med. 1:1995;282-284.
20. Krasagakis K., Tholke D., Farthmann B., Eberle J., Mansmann U., Orfanos C.E. Elevated plasma levels of transforming growth factor (TGF)-beta1 and TGF-beta2 in patients with disseminated malignant melanoma. Br. J. Cancer. 77:1998;1492-1494.
21. Kong F.M., Anscher M.S., Murase T., Abbott B.D., Iglehart J.D., Jirtle R.L. Elevated plasma transforming growth factor-beta 1 levels in breast cancer patients decrease after surgical removal of the tumor. Ann. Surg. 222:1995;155-162.
22. Pfeiffer A., Middelberg-Bisping K., Drewes C., Schatz H. Elevated plasma levels of transforming growth factor-beta 1 in NIDDM. Diabetes Care. 19:1996;1113-1117.
23. Snowden N., Coupes B., Herrick A., Illingworth K., Jayson M.I., Brenchley P.E. Plasma TGF beta in systemic sclerosis: a cross-sectional study. Ann. Rheum. Dis. 53:1994;763-767.
24. Grainger D.J., Kemp B.R., Metcalfe J.C., Liu A.C., Lawn R.M., Williams N.R., Grace A.A., Schofield P.M., Chauhan A. The serum concentration of active transforming growth-factor-beta is severely depressed in advanced atherosclerosis. Nature Medicine. 1:1995;74-79.
25. Wang X.L., Liu S.X., Wilcken D.E.L. Circulating transforming growth factor beta 1 and coronary artery disease. Cardiovascular Research. 34:1997;404-410.
26. Wakefield L.M., Letterio J.J., Chen T., Danielpour D., Allison R.S., Pai L.H., Denicoff A.M., Noone M.H., Cowan K.H., O'Shaughnessy J.A., Sporn M.B. Transforming growth factor-beta1 circulates in normal human plasma and is unchanged in advanced metastatic breast cancer. Clin. Cancer Res. 1:1995;129-136.
27. Danielpour D., Dart L.L., Flanders K.C., Roberts A.B., Sporn M.B. Immunodetection and quantitation of the two forms of transforming growth factor-beta (TGF-beta 1 and TGF-beta 2) secreted by cells in culture. J. Cell Physiol. 138:1989;79-86.
28. Danielpour D., Kim K.Y., Dart L.L., Watanabe S., Roberts A.B., Sporn M.B. Sandwich enzyme-linked immunosorbent assays (SELISAs) quantitate and distinguish two forms of transforming growth factor-beta (TGF-beta 1 and TGF-beta 2) in complex biological fluids. Growth Factors. 2:1989;61-71.
29. Danielpour D. Improved sandwich enzyme-linked immunosorbent assays for transforming growth factor beta 1. J. Immunol. Methods. 158:1993;17-25.
30. Kropf J., Schurek J.O., Wollner A., Gressner A.M. Immunological measurement of transforming growth factor-beta 1 (TGF-beta1) in blood; assay development and comparison. Clin. Chem. 43:1997;1965-1974.
31. Tsang M.L., Zhou L., Zheng B.L., Wenker J., Fransen G., Humphrey J., Smith J.M., O'Connor-McCourt M., Lucas R., Weatherbee J.A. Characterization of recombinant soluble human transforming growth factor-beta receptor type II (rhTGF-beta sRII). Cytokine. 7:1995;389-397.
32. Gentry L.E., Lioubin M.N., Purchio A.F., Marquardt H. Molecular events in the processing of recombinant type 1 pre-pro-transforming growth factor beta to the mature polypeptide. Mol. Cell Biol. 8:1988;4162-4168.
33. Garrigue-Antar L., Barbieux I., Lieubeau B., Boisteau O., Gregoire M. Optimisation of CCL64-based bioassay for TGF-beta. J. Immunol. Methods. 186:1995;267-274.
34. van Waarde M.A., van Assen A.J., Kampinga H.H., Konings A.W., Vujaskovic Z. Quantification of transforming growth factor-beta in biological material using cells transfected with a plasminogen activator inhibitor-1 promoter-luciferase construct. Anal. Biochem. 247:1997;45-51.
35. Grainger D.J., Mosedale D.E., Metcalfe J.C., Weissberg P.L., Kemp P.R. Active and acid-activatable TGF-beta in human sera, platelets and plasma. Clinica Chimica Acta. 235:1995;11-31.
36. Grainger D.J., Wakefield L., Bethell H.W., Farndale R.W., Metcalfe J.C. Release and activation of platelet latent TGF-beta in blood-clots during dissolution with plasmin. Nature Medicine. 1:1995;932-937.
37. Nishimura N., Harada-Shiba M., Tajima S., Sugano R., Yamamura T., Qiang Q.Z., Yamamoto A. Acquisition of secretion of transforming growth factor-beta 1 leads to autonomous suppression of scavenger receptor activity in a monocyte-macrophage cell line, THP-1. J. Biol. Chem. 273:1998;1562-1567.
38. Grotendorst G.R., Smale G., Pencev D. Production of transforming growth factor beta by human peripheral blood monocytes and neutrophils. J. Cell Physiol. 140:1989;396-402.
39. Assoian R.K., Fleurdelys B.E., Stevenson H.C., Miller P.J., Madtes D.K., Raines E.W., Ross R., Sporn M.B. Expression and secretion of type beta transforming growth factor by activated human macrophages. Proc. Natl. Acad. Sci., USA. 84:1987;6020-6024.
40. Mohan S, Baylink DJ. Bone growth factors. Clin Orthop 1991:30-48
41. Pfeilschifter J., Erdmann J., Storch S., Ziegler R., Weinreb M. Changes in the concentration of insulin-like growth factor I and transforming growth factor beta1 in rat femoral bone during growth. Calcif. Tissue Int. 64:1999;78-82.
42. Grainger D.J., Kemp P.R., Liu A.C., Lawn R.M., Metcalfe J.C. Activation of transforming growth-factor-beta is inhibited in transgenic apolipoprotein(a) mice. Nature. 370:1994;460-462.
43. Zioncheck T.F., Chen S.A., Richardson L., Moraworms M., Lucas C., Lewis D., Green J.D., Mordenti J. Pharmacokinetics and tissue distribution of recombinant human transforming growth-factor beta(1) after topical and intravenous administration in male-rats. Pharmaceutical Research. 11:1994;213-220.
44. Wakefield L.M., Winokur T.S., Hollands R.S., Christopherson K., Levinson A.D., Sporn M.B. Recombinant latent transforming growth factor beta 1 has a longer plasma half-life in rats than active transforming growth factor beta 1, and a different tissue distribution. J. Clin. Invest. 86:1990;1976-1984.
45. Coffey R.J. Jr, Kost L.J., Lyons R.M., Moses H.L., LaRusso N.F. Hepatic processing of transforming growth factor beta in the rat: uptake, metabolism, and biliary excretion. J. Clin. Invest. 80:1987;750-757.
46. Dickson K., Philip A., Warshawsky H., O'Connor-McCourt M., Bergeron J.J. Specific binding of endocrine transforming growth factor-beta 1 to vascular endothelium. J. Clin. Invest. 95:1995;2539-2554.
47. Murakami K., Takemura T., Hino S., Yoshioka K. Urinary transforming growth factor-beta in patients with glomerular diseases. Pediatr. Nephrol. 11:1997;334-336.
48. Philip A., O'Connor-McCourt M.D. Interaction of transforming growth factor-beta 1 with alpha 2-macroglobulin. Role in transforming growth factor-beta 1 clearance. J. Biol. Chem. 266:1991;22290-22296.
49. LaMarre J., Hayes M.A., Wollenberg G.K., Hussaini I., Hall S.W., Gonias S.L. An alpha-2-macroglobulin receptor-dependent mechanism for the plasma-clearance of transforming growth factor-beta-1 in mice. Journal of Clinical Investigation. 87:1991;39-44.
50. Narita M., Bu G., Herz J., Schwartz A.L. Two receptor systems are involved in the plasma clearance of tissue-type plasminogen activator (t-PA) in vivo. J. Clin. Invest. 96:1995;1164-1168.
51. Grainger D.J., Heathcote K., Chiano M., Snieder H., Kemp P.R., Metcalfe J.C., Carter N.D., Spector T.D. Genetic control of the circulating concentration of transforming growth factor type beta1. Hum. Mol. Genet. 8:1999;93-97.
52. Junker U., Knoefel B., Nuske K., Rebstock K., Steiner T., Wunderlich H., Junker K., Reinhold D. Transforming growth factor beta 1 is significantly elevated in plasma of patients suffering from renal cell carcinoma. Cytokine. 8:1996;794-798.
53. Chaudhry A., Oberg K., Gobl A., Heldin C.H., Funa K. Expression of transforming growth factors beta 1, beta 2, beta 3 in neuroendocrine tumors of the digestive system. Anticancer Res. 14:1994;2085-2091.
54. Ito N., Kawata S., Tamura S., Takaishi K., Shirai Y., Kiso S., Yabuuchi I., Matsuda Y., Nishioka M., Tarui S. Elevated levels of transforming growth factor beta messenger RNA and its polypeptide in human hepatocellular carcinoma. Cancer Res. 51:1991;4080-4083.
55. Grainger D.J., Witchell C.M., Metcalfe J.C. Tamoxifen elevates transforming growth-factor-beta and suppresses diet-induced formation of lipid lesions in mouse aorta. Nature Medicine. 1:1995;1067-1073.
56. Kopp A., Jonat W., Schmahl M., Knabbe C. Transforming growth factor beta 2 (TGF-beta 2) levels in plasma of patients with metastatic breast cancer treated with tamoxifen. Cancer Res. 55:1995;4512-4515.
57. Knabbe C., Zugmaier G., Schmahl M., Dietel M., Lippman M.E., Dickson R.B. Induction of transforming growth factor beta by the antiestrogens droloxifene, tamoxifen, and toremifene in MCF-7 cells. Am. J. Clin. Oncol. 14:1991;S15-S20.
58. Kirschenlohr H.L., Metcalfe J.C., Weissberg P.L., Grainger D.J. Proliferation of human aortic vascular smooth-muscle cells in culture is modulated by active TGF-beta. Cardiovascular Research. 29:1995;848-855.
59. Mosedale D.E., Grainger D.J. An antibody present in normal human serum inhibits the binding of cytokines to their receptors in an in vitro system. Biochem. J. 343:1999;125-133.
60. Galili U. Evolution and pathophysiology of the human natural anti-alpha-galactosyl IgG (anti-Gal) antibody. Springer Semin. Immunopathol. 15:1993;155-171.
61. Massague J. The transforming growth factor-beta family. Annu. Rev. Cell Biol. 6:1990;597-641.
62. Kehrl J.H., Roberts A.B., Wakefield L.M., Jakowlew S., Sporn M.B., Fauci A.S. Transforming growth factor beta is an important immunomodulatory protein for human B lymphocytes. J. Immunol. 137:1986;3855-3860.
63. Gamble J.R., Khew-Goodall Y., Vadas M.A. Transforming growth factor-beta inhibits E-selectin expression on human endothelial cells. J. Immunol. 150:1993;4494-4503.
64. Stavnezer J. Regulation of antibody production and class switching by TGF-beta. J. Immunol. 155:1995;1647-1651.
65. Mustoe T.A., Pierce G.F., Thomason A., Gramates P., Sporn M.B., Deuel T.F. Accelerated healing of incisional wounds in rats induced by transforming growth factor-beta. Science. 237:1987;1333-1336.
66. Shah M., Revis D., Herrick S., Baillie R., Thorgeirson S., Ferguson M., Roberts A. Role of elevated plasma transforming growth factor-beta1 levels in wound healing. Am. J. Pathol. 154:1999;1115-1124.
67. Shah M., Foreman D.M., Ferguson M.W. Neutralisation of TGF-beta 1 and TGF-beta 2 or exogenous addition of TGF-beta 3 to cutaneous rat wounds reduces scarring. J. Cell Sci. 108:1995;985-1002.
68. Adzick N.S., Lorenz H.P. Cells, matrix, growth factors, and the surgeon. The biology of scarless fetal wound repair. Ann. Surg. 220:1994;10-18.
69. Higley H., Persichitte K., Chu S., Waegell W., Vancheeswaran R., Black C. Immunocytochemical localization and serologic detection of transforming growth factor beta 1. Association with type I procollagen and inflammatory cell markers in diffuse and limited systemic sclerosis, morphea, and Raynaud's phenomenon. Arthritis Rheum. 37:1994;278-288.
70. Muller F., Aukrust P., Nilssen D.E., Froland S.S. Reduced serum level of transforming growth factor-beta in patients with IgA deficiency. Clin. Immunol. Immunopathol. 76:1995;203-208.
71. Hayasaka A., Suzuki N., Fukuyama E., Kanda Y. Plasma levels of transforming growth factor beta 1 in chronic liver disease. Clin. Chim. Acta. 244:1996;117-119.
72. Zauli G., Gugliotta L., Catani L., Vianelli N., Borgatti P., Belmonte M.M., Tura S. Increased serum levels of transforming growth factor beta-1 in patients affected by thrombotic thrombocytopenic purpura (TTP): its implications on bone marrow haematopoiesis. Br. J. Haematol. 84:1993;381-386.
73. Murase T., Jirtle R.L., McDonald G.B. Transforming growth factor-beta plasma concentrations in patients with leukemia and lymphoma receiving chemoradiotherapy and marrow transplantation. Blood. 83:1994;2383. (abstract).
74. Shirai Y., Kawata S., Ito N., Tamura S., Takaishi K., Kiso S., Tsushima H., Matsuzawa Y. Elevated levels of plasma transforming growth factor-beta in patients with hepatocellular carcinoma. Jpn. J. Cancer R. 83:1992;676-679.
75. Anscher M.S., Peters W.P., Reisenbichler H., Petros W.P., Jirtle R.L. Transforming growth factor beta as a predictor of liver and lung fibrosis after autologous bone marrow transplantation for advanced breast cancer. N. Engl. J. Med. 328:1993;1592-1598.
76. Szymkowiak C.H., Mons I., Gross W.L., Kekow J. Determination of transforming growth factor beta 2 in human blood samples by ELISA. J. Immunol. Methods. 184:1995;263-271.
77. Claudepierre P., Rymer J.C., Authier F.J., Allanore Y., Larget-Piet B., Gherardi R., Chevalier X. A relationship between TGF-beta 1 or IL-6 plasma levels and clinical features of spondyloarthropathies. Br. J. Rheumatol. 36:1997;400-401.
78. Zauli G., Gugliotta L., Catani L., Vianelli N., Borgatti P., Belmonte M.M., Tura S. Increased serum levels of transforming growth factor beta-1 in patients affected by thrombotic thrombocytopenic purpura (TTP): its implications on bone marrow haematopoiesis. Br. J. Haematol. 84:1993;381-386.
79. Szymkowiak C.H., Mons I., Gross W.L., Kekow J. Determination of transforming growth factor beta 2 in human blood samples by ELISA. J. Immunol. Methods. 184:1995;263-271.
80. Bennett A.L., Chao C.C., Hu S., Buchwald D., Fagioli L.R., Schur P.H., Peterson P.K., Komaroff A.L. Elevation of bioactive transforming growth factor-beta in serum from patients with chronic fatigue syndrome. J. Clin. Immunol. 17:1997;160-166.
81. Djurovic S., Schjetlein R., Wisloff F., Haugen G., Husby H., Berg K. Plasma concentrations of Lp(a) lipoprotein and TGF-beta 1 are altered in preeclampsia. Clin. Genet. 52:1997;371-376.